Moderna News

Nature reports on a positive trial for Moderna's cancer vaccine, highlighting its promise for treating cancer patients and emphasizing the need to accelerate re

Moderna's mRNA melanoma vaccine, intismeran, has shown promise in early trials by slowing the recurrence of skin cancer in patients. This development suggests t

Moderna's stock closed up 14.36% at $158.83 following an upgrade from Wolfe, raising questions about its future trajectory.

A personalized cancer vaccine developed by Moderna and Merck has shown success in a final-stage melanoma trial. Researchers are hopeful this approach could be u

The article explains how Moderna's new melanoma vaccine works and explores its potential to treat other cancers. Melanoma is highlighted as the most aggressive

Moderna's stock plunged 25%, wiping out $18 billion, despite the biotech giant announcing positive trial results for a cancer vaccine, as investors pulled back

Merck and Moderna announced that their cancer vaccine for melanoma successfully met its primary and key secondary endpoints in a Phase 3 trial, showing improved

Moderna's new mRNA cancer vaccine is designed to combat melanoma, the most aggressive form of skin cancer, which causes approximately 2,600 deaths annually in t

Moderna's personalized mRNA cancer vaccine achieved key goals in a Phase 3 melanoma trial, leading to a significant stock rally. This breakthrough offers new ho

Moderna is placing significant hope on its new 'game-changer' technology for cancer vaccines. This technology, which was also behind the successful Covid jabs,

A personalized cancer vaccine developed by Merck and Moderna shows promise for melanoma patients, significantly reducing cancer recurrence when combined with Ke

Moderna Inc.'s shares experienced a record 177% surge, resulting in a "painful" $5.5 billion loss for short sellers. These investors had bet on the vaccine make

Moderna and Merck announced that a new personalized mRNA vaccine significantly reduced the risk of melanoma recurrence and spread in a late-stage trial, marking

US stock markets rose as easing bond yields and a surge in Moderna shares boosted investor confidence, despite Federal Reserve minutes highlighting inflation co

Merck and Moderna announced that their personalized mRNA vaccine successfully prevented melanoma recurrence in high-risk patients during a late-stage trial, tho

Moderna co-founder Robert Langer has regained his billionaire status after Moderna's stock more than doubled following positive results from a late-stage trial

Moderna and Merck's personalized mRNA cancer vaccine has met its primary goals in a Phase 3 trial for high-risk melanoma, marking a significant breakthrough and

Moderna co-founder Robert Langer has regained his billionaire status after the biotech giant's shares doubled in value following favorable results from a late-s

Moderna and Merck have announced that their experimental mRNA vaccine has shown success in preventing the return and spread of melanoma in high-risk patients. T

Moderna's stock surged by 120% following positive Phase 3 trial results for its mRNA cancer vaccine when combined with Merck's Keytruda, offering new hope for m

Moderna's stock surged after the company and Merck announced "landmark moment" study results for their melanoma vaccine trial, showing significant progress in t

Moderna's share price has nearly doubled due to optimism surrounding a potential breakthrough in personalized cancer treatment. This surge reflects investor con

Moderna shares surged 135% after its personalized mRNA cancer vaccine, combined with Keytruda, showed positive results in a late-stage trial for melanoma, signi

Moderna and Merck have reported promising results from a late-stage trial combining Moderna's mRNA therapy, intismeran, with Merck's Keytruda for melanoma patie